Protein Kinase Inhibitors: all 15,147 studies that test it

Page 31 of 152. Open to participants first (2,533), then studies with results posted, then the rest; newest registration first within each.

• Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell LymphomaCompletedNCT04436107Phase 1Results posted
• NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)CompletedNCT04435665Phase 2Results posted
• Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)CompletedNCT04434937Phase 2Results posted
• A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease SymptomsCompletedNCT04430855Phase 2Results posted
• Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)CompletedNCT04428151Phase 2Results posted
• Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping MutationTerminatedNCT04427072Phase 3Results posted
• Infigratinib in Recurrent High-Grade Glioma PatientsTerminatedNCT04424966Early Phase 1Results posted
• A Study of Baricitinib (LY3009104) in Participants With COVID-19CompletedNCT04421027Phase 3Results posted
• Olaparib With Ceralasertib in Recurrent OsteosarcomaActive, not recruitingNCT04417062Phase 2Results posted
• Tofacitinib for Treatment of Moderate COVID-19TerminatedNCT04415151Phase 2Results posted
• A Study of Opaganib in Coronavirus Disease 2019 PneumoniaCompletedNCT04414618Phase 2Results posted
• Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa TreatmentTerminatedNCT04414514Phase 2Results posted
• TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATECompletedNCT04413617Phase 2Results posted
• Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)CompletedNCT04411641Phase 3Results posted
• Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)CompletedNCT04410991Phase 3Results posted
• Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)CompletedNCT04410978Phase 3Results posted
• Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway MutationsActive, not recruitingNCT04409639Phase 2Results posted
• Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate CancerCompletedNCT04408924Phase 2Results posted
• PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without CancerTerminatedNCT04404361Phase 2Results posted
• TD-0903 for ALI Associated With COVID-19CompletedNCT04402866Phase 2Results posted
• Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell LymphomaCompletedNCT04402138Phase 2Results posted
• Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular CarcinomaCompletedNCT04401800Phase 2Results posted
• Adaptive COVID-19 Treatment Trial 2 (ACTT-2)CompletedNCT04401579Phase 3Results posted
• Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN StudyCompletedNCT04400474Phase 2Results posted
• Trial of Imatinib for Hospitalized Adults With COVID-19TerminatedNCT04394416Phase 3Results posted
• Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After ImmunotherapyTerminatedNCT04393454Phase 2Results posted
• Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell CarcinomaActive, not recruitingNCT04393350Phase 2Results posted
• Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E MutationTerminatedNCT04390243Phase 2Results posted
• Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized ParticipantsCompletedNCT04382586Phase 2Results posted
• Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.CompletedNCT04380688Phase 2Results posted
• Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)TerminatedNCT04377620Phase 3Results posted
• Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary InjuryCompletedNCT04375397Phase 2Results posted
• Study With Afuresertib and Paclitaxel in Platinum Resistant OvarianCompletedNCT04374630Phase 2Results posted
• Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRSCompletedNCT04374149Phase 2Results posted
• Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung CancerTerminatedNCT04373369Phase 2Results posted
• Duvelisib to Combat COVID-19CompletedNCT04372602Phase 2Results posted
• Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing SurgeryTerminatedNCT04370509Phase 2Results posted
• A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With NeratinibCompletedNCT04366713Phase 2Results posted
• Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine StormCompletedNCT04362137Phase 3Results posted
• Study of Lorlatinib In People With ALK-positive Non-small Cell Lung CancerCompletedNCT04362072Phase 4Results posted
• Itacitinib in Advanced Hepatocellular CarcinomaCompletedNCT04358185Phase 1Results posted
• Axitinib Monotherapy With Early Dynamic Contrast Enhanced Ultrasound Monitoring in Chemorefractory Third Line Metastatic Colorectal CancerCompletedNCT04355156Phase 2Results posted
• A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung CancerActive, not recruitingNCT04351555Phase 3Results posted
• Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung CancerTerminatedNCT04348292Phase 1Results posted
• Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.CompletedNCT04346199Phase 2Results posted
• Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast CancerActive, not recruitingNCT04345913Phase 1/2Results posted
• Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical TherapyCompletedNCT04345367Phase 3Results posted
• Sirolimus Treatment in Hospitalized Patients With COVID-19 PneumoniaCompletedNCT04341675Phase 2Results posted
• Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell TransplantationCompletedNCT04339101Phase 2Results posted
• Study of Evobrutinib in Participants With RMS (evolutionRMS 2)TerminatedNCT04338061Phase 3Results posted
• Study of Evobrutinib in Participants With RMS (evolutionRMS 1)TerminatedNCT04338022Phase 3Results posted
• Talazoparib and Axitinib for People With Previously Treated Advanced Kidney CancerCompletedNCT04337970Phase 1/2Results posted
• Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative DisorderTerminatedNCT04337827Phase 2Results posted
• Study Of Intrabucally Administered Electromagnetic Fields and RegorafenibTerminatedNCT04327700Phase 2Results posted
• AflacLL1901 (CHOA-AML)TerminatedNCT04326439Phase 2Results posted
• A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal CancerCompletedNCT04322539Phase 3Results posted
• Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment TrialActive, not recruitingNCT04320888Phase 2Results posted
• Cabozantinib in Patients With Hepatocellular Carcinoma (ACTION)CompletedNCT04316182Phase 2Results posted
• Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By GenomicsTerminatedNCT04315233Phase 1Results posted
• Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older HumansCompletedNCT04313634Phase 2Results posted
• Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D MelanomaTerminatedNCT04310397Phase 2Results posted
• Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast CancerActive, not recruitingNCT04305496Phase 3Results posted
• Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast CancerTerminatedNCT04305236Phase 2Results posted
• Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host DiseaseCompletedNCT04294641Phase 2Results posted
• Safety and Efficacy of Pemigatinib in Patients With High-risk Urothelial Cancer After Radical SurgeryTerminatedNCT04294277Phase 2Results posted
• Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer PatientsActive, not recruitingNCT04293393Phase 2Results posted
• Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular SchwannomasCompletedNCT04283669Phase 2Results posted
• A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)CompletedNCT04282980Phase 2Results posted
• Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and TislelizumabCompletedNCT04282018Phase 1/2Results posted
• Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 MutationCompletedNCT04281498Phase 2Results posted
• A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET ActivationActive, not recruitingNCT04280081Phase 2Results posted
• Ibrutinib + Venetoclax in Untreated WMActive, not recruitingNCT04273139Phase 2Results posted
• Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)TerminatedNCT04267120Phase 2Results posted
• Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid TumorsActive, not recruitingNCT04266912Phase 1/2Results posted
• Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)TerminatedNCT04264442Phase 2Results posted
• Renal Impairment Study of PF-06700841CompletedNCT04260464Phase 1Results posted
• Everolimus Plus Mycophenolic Acid for Kidney Preservation in Liver Transplant Recipients With Impaired Kidney FunctionTerminatedNCT04258423Phase 3Results posted
• Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell LymphomaActive, not recruitingNCT04257578Phase 1/2Results posted
• Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN LossTerminatedNCT04251533Phase 3Results posted
• Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung CancerActive, not recruitingNCT04250545Phase 1Results posted
• Study to Investigate the Safety and Efficacy of K-321 in Patients With Fuchs Endothelial Corneal Dystrophy (FECD) Following DescemetorhexisCompletedNCT04250207Phase 2Results posted
• Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory TumorsTerminatedNCT04249843Phase 1Results posted
• Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)CompletedNCT04248829Phase 3Results posted
• Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RACompletedNCT04247815Phase 2Results posted
• Tofacitinib for Immune Skin Conditions in Down SyndromeCompletedNCT04246372Phase 2Results posted
• Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)TerminatedNCT04246177Phase 3Results posted
• A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)TerminatedNCT04240002Phase 1/2Results posted
• Ibrutinib and Rituxan for Chronic GVHDTerminatedNCT04235036Phase 2Results posted
• Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene MutationsCompletedNCT04233567Phase 2Results posted
• Trial of eRapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active SurveillanceCompletedNCT04230499Phase 2Results posted
• Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT StudyTerminatedNCT04230304Phase 2Results posted
• Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial CancerTerminatedNCT04228042Phase 1/2Results posted
• A Study to Investigate the Effect of Impaired Hepatic Function on the Pharmacokinetics of Entrectinib in Volunteers With Different Levels of Hepatic FunctionCompletedNCT04226833Phase 1Results posted
• Phase 2a Study of ZW25 in Combination With Palbociclib Plus FulvestrantCompletedNCT04224272Phase 2Results posted
• Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy ParticipantsCompletedNCT04223635Early Phase 1Results posted
• A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT04222972Phase 3Results posted
• Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node InvolvementTerminatedNCT04221438Phase 2Results posted
• Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the ExtremitiesTerminatedNCT04220229Phase 1/2Results posted
• ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase InhibitorTerminatedNCT04216563Phase 2Results posted
• Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN AlterationsTerminatedNCT04216472Phase 2Results posted

← Protein Kinase Inhibitors overview